<DOC>
	<DOCNO>NCT02171572</DOCNO>
	<brief_summary>The objective current study investigate safety , tolerability , pharmacokinetics dabigatran etexilate follow oral administration single multiple oral dos ( 110mg , 150 mg b.i.d. , 7 day ) healthy Chinese subject .</brief_summary>
	<brief_title>Single Multiple Oral Doses Dabigatran Etexilate Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Healthy subject accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR body temperature ) , 12lead ECG , clinical laboratory test No find clinical relevance . No evidence clinically relevant concomitant disease . Age : ≥18 ≤45 year . Body Mass Index ( BMI ) : ≥18 &lt; 25 kg/m2 . Signed date write informed consent prior admission trial accordance Chinese GCP . Current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder . Subject use adequate form contraception time first dose Day 1 endof study examination . Current diseases central nervous system ( epilepsy ) , psychiatric disorder neurological disorder . History clinically significant orthostatic hypotension , clinically significant current past fainting spell blackout . Chronic relevant acute infection . History allergy/hypersensitivity ( include drug allergy ) deem relevant safety assessment judge investigator ( exclude asymptomatic seasonal rhinitis/hay fever ) bleed disorder include prolonged habitual bleeding hematologic disease . cerebral bleeding ( e.g . car accident ) . concussion ( head trauma result injure brain ) without loss consciousness . Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives , whichever short , respective drug prior administration trial . Use aspirin ( include overthecounter medication ) , antiplatelet agent like ticlopidine dipyridamole , chronic administration nonsteroidal antiinflammatory drug ( NSAID ) , coumadin like anticoagulant , chronic use corticosteroid , heparin fibrinolytic agent within 14 day prior administration endofstudy examination . Participation another trial investigational drug within 3 month prior administration endofstudy examination . Smoker ( &gt; 10 cigarettes/day inability refrain smoke trial ) . Alcohol abuse ( 60 g/day ; confirm interview ) . Drug abuse ( confirm interview ) . Blood donation ( 100 mL 3 month prior screen blood donation screen endofstudy examination ) . Excessive physical activity ( within 7 day prior first drug administration endofstudy examination ) . Any laboratory value outside reference range clinical relevance . Known hypersensitivity investigational drug excipients . Subject judge ineligible investigator subinvestigator . History familial bleeding disorder . Thrombocytes &lt; 100×109 . Pregnant female subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>